Education
About Us
Working with TipRanks
Follow Us
Neurocrine Biosciences (NBIX)
:NBIX
NBIX Analyst Ratings
Strong Buy
22 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NBIX Stock 12 Month Forecast
Average Price Target
$169.27
▲(17.82% Upside)
| Highest Price Target$200.00 | Average Price Target$169.27 | Lowest Price Target$124.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
RBC Capital
$156
Buy
8.58%
Upside
Reiterated
10/23/25
Citi
$175
Buy
21.81%
Upside
Initiated
10/21/25
Strong Buy Rating for Neurocrine Due to Robust Pipeline and Strategic Growth PotentialWe are initiating coverage of NBIX with a Buy/High Risk rating and a $175 TP . The success of NBIX’s commercial pipeline this past year has been overshadowed by concerns around both Ingrezza’s ability to maintain its competitive advantage as the highest selling VMAT2i on the market, and the readthrough from Austedo’s upcoming Medicare price negotiations. However, we believe that Ingrezza is likely well-positioned to, at the very least, maintain its current market share given 1) Ingrezza’s best-in-class profile, and 2) pricing flexibility post-2027 to offer higher rebates to incentivize inclusion within formularies. Meanwhile, Crenessity’s launch appears promising, and given a lack of competitors, likely to continue accelerating to >$1B in peak, royalty-adjusted revenue.
Morgan Stanley
$163→$168
Buy
16.93%
Upside
Reiterated
10/20/25
Wells Fargo
$180
Buy
25.29%
Upside
Reiterated
10/13/25
UBS
$188→$195
Buy
35.73%
Upside
Reiterated
10/09/25
Bank of America Securities
$191
Buy
32.94%
Upside
Reiterated
10/03/25
Leerink Partners
―
Buy
―
Reiterated
09/23/25
William Blair
―
Buy
―
Reiterated
09/22/25
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA) and Neurocrine (NASDAQ: NBIX)We believe osavampator’s safety profile is clearly differentiated from prior orthosteric agonist approaches developed by Eli Lilly (LY 451646 [LLY $751.99]), Biogen (BIIB 104 [BIIB $142.50; Outperform]), and GSK (GSK 729327 [GSK $40.67]). We note that Draig Therapeutics (private) recently launched (see here) and plans to commence a Phase II clinical trial in MDD for DT-101, another AMPA receptor after successfully completing a Phase Ia trial in 60 subjects demonstrating safety and target engagement.
Needham
$161→$170
Buy
18.33%
Upside
Assigned
09/22/25
Stifel Nicolaus
$174
Buy
21.11%
Upside
Reiterated
09/22/25
Truist Financial
―
Buy
―
Reiterated
09/22/25
Jefferies
$160→$169
Buy
17.63%
Upside
Reiterated
09/22/25
BMO Capital
$124
Hold
-13.69%
Downside
Reiterated
09/22/25
Piper Sandler
$175
Buy
21.81%
Upside
Reiterated
09/22/25
Evercore ISI
$200
Buy
39.21%
Upside
Reiterated
09/19/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
$156
Buy
8.58%
Upside
Reiterated
10/23/25
Citi
$175
Buy
21.81%
Upside
Initiated
10/21/25
Strong Buy Rating for Neurocrine Due to Robust Pipeline and Strategic Growth PotentialWe are initiating coverage of NBIX with a Buy/High Risk rating and a $175 TP . The success of NBIX’s commercial pipeline this past year has been overshadowed by concerns around both Ingrezza’s ability to maintain its competitive advantage as the highest selling VMAT2i on the market, and the readthrough from Austedo’s upcoming Medicare price negotiations. However, we believe that Ingrezza is likely well-positioned to, at the very least, maintain its current market share given 1) Ingrezza’s best-in-class profile, and 2) pricing flexibility post-2027 to offer higher rebates to incentivize inclusion within formularies. Meanwhile, Crenessity’s launch appears promising, and given a lack of competitors, likely to continue accelerating to >$1B in peak, royalty-adjusted revenue.
Morgan Stanley
$163→$168
Buy
16.93%
Upside
Reiterated
10/20/25
Wells Fargo
$180
Buy
25.29%
Upside
Reiterated
10/13/25
UBS
$188→$195
Buy
35.73%
Upside
Reiterated
10/09/25
Bank of America Securities
$191
Buy
32.94%
Upside
Reiterated
10/03/25
Leerink Partners
―
Buy
―
Reiterated
09/23/25
William Blair
―
Buy
―
Reiterated
09/22/25
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA) and Neurocrine (NASDAQ: NBIX)We believe osavampator’s safety profile is clearly differentiated from prior orthosteric agonist approaches developed by Eli Lilly (LY 451646 [LLY $751.99]), Biogen (BIIB 104 [BIIB $142.50; Outperform]), and GSK (GSK 729327 [GSK $40.67]). We note that Draig Therapeutics (private) recently launched (see here) and plans to commence a Phase II clinical trial in MDD for DT-101, another AMPA receptor after successfully completing a Phase Ia trial in 60 subjects demonstrating safety and target engagement.
Needham
$161→$170
Buy
18.33%
Upside
Assigned
09/22/25
Stifel Nicolaus
$174
Buy
21.11%
Upside
Reiterated
09/22/25
Truist Financial
―
Buy
―
Reiterated
09/22/25
Jefferies
$160→$169
Buy
17.63%
Upside
Reiterated
09/22/25
BMO Capital
$124
Hold
-13.69%
Downside
Reiterated
09/22/25
Piper Sandler
$175
Buy
21.81%
Upside
Reiterated
09/22/25
Evercore ISI
$200
Buy
39.21%
Upside
Reiterated
09/19/25
Best Analysts Covering Neurocrine
1 Month
xxx
Success Rate
12/20 ratings generated profit
Average Return
+1.49%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +1.49% per trade.
3 Months
xxx
Success Rate
11/17 ratings generated profit
Average Return
+2.54%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +2.54% per trade.
1 Year
Success Rate
20/27 ratings generated profit
Average Return
+10.83%
reiterated a buy rating 22 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 74.07% of your transactions generating a profit, with an average return of +10.83% per trade.
2 Years
xxx
Success Rate
14/17 ratings generated profit
Average Return
+14.07%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +14.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NBIX Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
19
10
2
1
0
Buy
24
52
41
52
22
Hold
5
6
4
5
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
68
47
58
24
Each month's total comprises the sum of three months' worth of ratings.
NBIX Financial Forecast
NBIX Stock Forecast FAQ
What is NBIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine Biosciences’s 12-month average price target is 169.27.
What is NBIX’s upside potential, based on the analysts’ average price target?
Neurocrine Biosciences has 17.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NBIX a Buy, Sell or Hold?
Neurocrine Biosciences has a consensus rating of Strong Buy which is based on 22 buy ratings, 3 hold ratings and 0 sell ratings.
What is Neurocrine Biosciences’s price target?
The average price target for Neurocrine Biosciences is 169.27. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $124.00. The average price target represents 17.82% Increase from the current price of $143.67.
The highest analyst price target is $200.00 ,the lowest forecast is $124.00. The average price target represents 17.82% Increase from the current price of $143.67.
What do analysts say about Neurocrine Biosciences?
Neurocrine Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
How can I buy shares of NBIX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.